Risankizumab Met Primary And Key Secondary Endpoints In 52-Week Phase 3 Maintenance Study In Ulcerative Colitis Patients
Portfolio Pulse from Benzinga Newsdesk
AbbVie announced positive top-line results from its Phase 3 COMMAND study, showing risankizumab achieved the primary endpoint of clinical remission at week 52, as well as key secondary endpoints in adult patients with moderately to severely active ulcerative colitis. The safety profile of risankizumab was consistent with previous studies, with no new safety risks observed.
June 15, 2023 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie's risankizumab met primary and key secondary endpoints in a Phase 3 study for ulcerative colitis patients, showing potential as an effective treatment option.
The positive top-line results from the Phase 3 COMMAND study indicate that risankizumab has the potential to be an effective treatment option for ulcerative colitis patients. This could lead to increased demand for the drug and potentially boost AbbVie's revenues, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100